Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8680515 | Alzheimer's & Dementia: Translational Research & Clinical Interventions | 2017 | 7 Pages |
Abstract
A biomarker risk assignment algorithm, using a combination of APOE, TOMM40â²523 genotype, and age, has been developed to assign near-term risk for developing the onset of mild cognitive impairment due to AD and is being used as an enrichment tool in an ongoing delay-of-onset clinical trial. Understanding the characterization of APOE and TOMM40 allele frequencies in the Japanese population is the first step in developing a risk algorithm for AD research and clinical applications for AD prevention in Japan.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Akira Nishimura, Hidenori Nonomura, Shingo Tanaka, Michihiro Yoshida, Yuka Maruyama, Yutaka Aritomi, Ann M. Saunders, Daniel K. Burns, Michael W. Lutz, Grant Runyan, Eric Lai, Kumar Budur, Allen D. Roses,